Poolbeg Pharma PLC (POLB)

London
9.10
+0.05(+0.55%)
  • Volume:
    1,024,948
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    9.10 - 9.10

POLB Overview

Prev. Close
9.05
Day's Range
9.1-9.1
Revenue
-
Open
9.05
52 wk Range
4-11.14
EPS
-0.01
Volume
1,024,948
Market Cap
45.5M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,913,003
P/E Ratio
-
Beta
1.92
1-Year Change
5.2%
Shares Outstanding
500,000,000
Next Earnings Date
-
What is your sentiment on Poolbeg Pharma?
or
Market is currently closed. Voting is open during market hours.

Poolbeg Pharma PLC News

Poolbeg Pharma PLC Company Profile

Poolbeg Pharma PLC Company Profile

Employees
7

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Read More

Analyst Price Target

Average16.50 (+81.32% Upside)
High18
Low15
Price9.1
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
  • I got the extra dividends wrong -just waiting to see what they come up with-if anything-prior to the 18/19? April release date on rht POLB dividend share-
    0
    • This share has some interesting products in the pipeline .It is been devolved out of Open Orphan.Well worth researching both companies-Orph gave its shareholders an exceptional dividend in POLB and is ue to announce a further 2 if not 3 dividends including a cash one before year end.
      0
      • Looks a load of rubbish like open orphan but what do i know
        0